BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) published the company’s Interim Report for the period January – September 2021 on Thursday, October 21, 2021, at 08:00 a.m. CET.
Halting the disease progression would lead to great benefits to patients, families and caregivers.
The medical need of treatments is high due to the lack of drugs affecting the underlying pathology.
BioArctic is committed to help people with neurodegenerative disorders
